{"id":"roflumilast-cream-0-3","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting phosphodiesterase-4, roflumilast decreases the levels of cyclic adenosine monophosphate (cAMP) in inflammatory cells, leading to a reduction in the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1β). This results in decreased inflammation and improved symptoms in patients with chronic obstructive pulmonary disease (COPD).","oneSentence":"Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:37.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06648772","phase":"PHASE3","title":"Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-11-14","conditions":"Plaque Psoriasis","enrollment":189},{"nctId":"NCT04286607","phase":"PHASE3","title":"Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-02-12","conditions":"Chronic Plaque Psoriasis","enrollment":333},{"nctId":"NCT05763082","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2023-02-07","conditions":"Plaque Psoriasis","enrollment":414},{"nctId":"NCT06440473","phase":"PHASE4","title":"Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin","status":"RECRUITING","sponsor":"Rao Dermatology","startDate":"2024-05-28","conditions":"Healthy Skin","enrollment":3},{"nctId":"NCT04655313","phase":"PHASE2","title":"Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-11-30","conditions":"Psoriasis, Plaque Psoriasis","enrollment":20},{"nctId":"NCT04746911","phase":"PHASE2","title":"Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-03-01","conditions":"Psoriasis, Plaque Psoriasis","enrollment":10},{"nctId":"NCT04211363","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-20","conditions":"Chronic Plaque Psoriasis","enrollment":439},{"nctId":"NCT04211389","phase":"PHASE3","title":"Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-17","conditions":"Chronic Plaque Psoriasis","enrollment":442},{"nctId":"NCT03638258","phase":"PHASE2","title":"The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-09-21","conditions":"Plaque Psoriasis","enrollment":331},{"nctId":"NCT03764475","phase":"PHASE2","title":"Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2018-12-18","conditions":"Plaque Psoriasis","enrollment":332}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zoryve","ARQ-151"],"phase":"phase_3","status":"active","brandName":"Roflumilast Cream 0.3%","genericName":"Roflumilast Cream 0.3%","companyName":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","companyId":"hangzhou-zhongmei-huadong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines. Used for Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}